These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 35967359)
21. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065 [TBL] [Abstract][Full Text] [Related]
22. Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study. Shirane R; Tang H; Hayashi K; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y; J Med Virol; 2017 Feb; 89(2):313-317. PubMed ID: 27420414 [TBL] [Abstract][Full Text] [Related]
23. Subsets of T-cells and in vitro cytokine production after measles and varicellae-zoster virus antigen stimulation in allogeneic BMT patients. Pauksen K; Sjölin J; Linde A; Andersson B; Lenkei R; Oberg G; Ljungman P Scand J Infect Dis; 1999; 31(1):43-9. PubMed ID: 10381217 [TBL] [Abstract][Full Text] [Related]
24. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134 [TBL] [Abstract][Full Text] [Related]
25. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Baumrin E; Izaguirre NE; Bausk B; Feeley MM; Bay CP; Yang Q; Ho VT; Baden LR; Issa NC Blood Adv; 2021 Mar; 5(6):1585-1593. PubMed ID: 33710336 [TBL] [Abstract][Full Text] [Related]
26. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. Bastidas A; de la Serna J; El Idrissi M; Oostvogels L; Quittet P; López-Jiménez J; Vural F; Pohlreich D; Zuckerman T; Issa NC; Gaidano G; Lee JJ; Abhyankar S; Solano C; Perez de Oteyza J; Satlin MJ; Schwartz S; Campins M; Rocci A; Vallejo Llamas C; Lee DG; Tan SM; Johnston AM; Grigg A; Boeckh MJ; Campora L; Lopez-Fauqued M; Heineman TC; Stadtmauer EA; Sullivan KM; JAMA; 2019 Jul; 322(2):123-133. PubMed ID: 31287523 [TBL] [Abstract][Full Text] [Related]
27. VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients. Conrad A; Boccard M; Valour F; Alcazer V; Tovar Sanchez AT; Chidiac C; Laurent F; Vanhems P; Salles G; Brengel-Pesce K; Meunier B; Trouillet-Assant S; Ader F; BMJ Open; 2019 Feb; 9(2):e026093. PubMed ID: 30772864 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine. Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990 [TBL] [Abstract][Full Text] [Related]
30. Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. Jamani K; MacDonald J; Lavoie M; Williamson TS; Brown CB; Chaudhry A; Jimenez-Zepeda VH; Duggan P; Tay J; Stewart D; Daly A; Storek J Blood Adv; 2016 Dec; 1(2):152-159. PubMed ID: 29296807 [TBL] [Abstract][Full Text] [Related]
31. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Ogonek J; Kralj Juric M; Ghimire S; Varanasi PR; Holler E; Greinix H; Weissinger E Front Immunol; 2016; 7():507. PubMed ID: 27909435 [TBL] [Abstract][Full Text] [Related]
32. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Arber DA; Orazi A; Hasserjian R; Thiele J; Borowitz MJ; Le Beau MM; Bloomfield CD; Cazzola M; Vardiman JW Blood; 2016 May; 127(20):2391-405. PubMed ID: 27069254 [TBL] [Abstract][Full Text] [Related]
33. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Swerdlow SH; Campo E; Pileri SA; Harris NL; Stein H; Siebert R; Advani R; Ghielmini M; Salles GA; Zelenetz AD; Jaffe ES Blood; 2016 May; 127(20):2375-90. PubMed ID: 26980727 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay. Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696 [TBL] [Abstract][Full Text] [Related]
36. Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA Class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation. Raeiszadeh M; Pachnio A; Begum J; Craddock C; Moss P; Chen FE Haematologica; 2015 Aug; 100(8):e318-22. PubMed ID: 25975839 [No Abstract] [Full Text] [Related]
37. Flow cytometric evaluation of lymphocyte transformation test based on 5-ethynyl-2'deoxyuridine incorporation as a clinical alternative to tritiated thymidine uptake measurement. Poujol F; Monneret G; Friggeri A; Rimmelé T; Malcus C; Poitevin-Later F; Pachot A; Lepape A; Textoris J; Venet F J Immunol Methods; 2014 Dec; 415():71-9. PubMed ID: 25450005 [TBL] [Abstract][Full Text] [Related]
38. Varicella-zoster virus-specific, cell-mediated immunity with interferon-gamma release assay after vaccination of college students with no or intermediate IgG antibody response. Terada K; Itoh Y; Fujii A; Kitagawa S; Ogita S; Ouchi K J Med Virol; 2015 Feb; 87(2):350-6. PubMed ID: 25080078 [TBL] [Abstract][Full Text] [Related]